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Abstract: Status epilepticus that cannot be controlled with first- and second-line agents is called
refractory status epilepticus (RSE), a condition that is associated with significant morbidity
and mortality. Most experts agree that treatment of RSE necessitates the use of continuous
infusion intravenous anesthetic drugs such as midazolam, propofol, pentobarbital, thiopental, and
ketamine, each of which has its own unique characteristics. This review compares the various
anesthetic agents while providing an approach to their use in adult patients, along with possible
associated complications.
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1. Introduction
Refractory status epilepticus (RSE) is defined as ongoing seizures that cannot be controlled with
first- and second-line agents and has an incidence ranging from 9% to 43% [1–6]. Some patients
fail to respond to third-line therapy, and are considered to have super-refractory SE (SRSE), the true
incidence of which is unknown. Both of these are associated with progressively-increasing morbidity
and mortality, and expert guidelines advocate early initiation of intravenous anesthetic agents to
maximize the chance of seizure cessation while minimizing the risk of long-term sequelae [7]. Despite
guideline recommendations, the optimal approach to management remains controversial due to a lack
of evidence from high quality clinical trials. The most commonly used continuous infusion intravenous
anesthetics (cIV-AEDs) include midazolam, propofol, and pentobarbital, though the use of ketamine
has also been increasingly described. (Note that outside the U.S., thiopental, rather than pentobarbital,
is often the barbiturate of choice, especially in Europe.) This article provides an overview of their use
in adult patients and the available clinical evidence. A summary of their pharmacologic properties is
provided in Table 1.
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Table 1. Pharmacology of Commonly Used CI Anesthetics for RSE.
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2. Approach to cIV Anesthetic Use
Most practitioners using cIV AEDs aim for a goal of seizure suppression or burst suppression,
but even more aggressive management including suppression of all background activity has been
proposed. [7] This has not been investigated in a systematic way, as the heterogeneous nature
and relative rarity of the disease process makes conducting large randomized controlled trials
challenging (as evidenced by the difficulty in enrolling patients in the only RCT attempted to date [7,8]).
Often, total seizure suppression cannot be achieved without inducing a therapeutic coma with a
burst-suppression pattern on electroencephalography (EEG) or, at times, even a completely isoelectric
EEG. A meta-analysis of cIV-AEDs for RSE found that titration of treatment to EEG background
suppression was associated with a significantly lower frequency of breakthrough seizures than titration
to seizure suppression, but was also associated with a significantly higher frequency of hypotension;
meanwhile, neither titration goal nor choice of anesthetic infusion (between propofol, midazolam, and
pentobarbital) was associated with a change in overall outcome [9].
There is also no consensus on the optimal duration of anesthetic infusions for RSE, though
guidelines traditionally recommend seizure control for 24–48 h, followed by a gradual wean of the
infusion [7]. Seizures that occur during weaning of the anesthetic are labeled as withdrawal seizures,
though there may also be later SE recurrence. Both of these necessitate resumption of the anesthetic
infusion, potentially at a higher dose and/or addition of another antiepileptic. It is important to keep
in mind that, while RSE carries a significant risk of poor outcome, multiple retrospective studies and
case series have shown the possibility of meaningful functional recovery even when SE resolution
required weeks or months, suggesting that there is no clear duration of SE or number of failures to
wean IV anesthetic infusions that should be considered futile [10–14].
Note that there is even less agreement in treating SRSE, when cIV-AEDs fail to control seizures.
The management of SRSE is outside the scope of this review, but combination therapy involves
adding another treatment that is often non-pharmacologic, like hypothermia [15] or ketogenic diet [16],
to ongoing treatment with cIV-AEDs. A relevant point worth noting, however, is that the use of
hypothermia leads to a decrease in overall metabolism, which may lead to an increase in the half-life
of the IV anesthetics referenced here.
3. Benzodiazepines: Midazolam
Midazolam administered as a continuous infusion has been a preferred treatment for RSE since the
1990s, with multiple case series and meta-analyses describing its successful use [9,15–20]. Its popularity
stems from its favorable properties, including a fast onset (1–5 min) and relatively short half-life (in the
range of 1–6 h) when used as a bolus or short-term infusion [21,22]. It also does not contain propylene
glycol, unlike lorazepam and diazepam, which obviates any concern for toxicity from propylene glycol
accumulation. Propylene glycol has been associated with hypotension, in addition to more severe
cardiac dysfunction and metabolic acidosis, though midazolam itself can cause hypotension.
Note that although midazolam has a relatively short half-life after a single dose, case reports
have demonstrated a significantly increased half-life after prolonged infusion, due to an increased free
fraction and volume of distribution and accumulation of its active metabolite, leading to a longer than
expected time to awakening after stopping an infusion [23,24]. Prolonged infusion can also lead to
tachyphylaxis, necessitating progressively higher doses to achieve the same effect. Midazolam cIV
causes respiratory depression, requiring intubation for the duration of therapy.
As with other benzodiazepines, midazolam potentiates the inhibitory action of gamma-
aminobutyric acid (GABA) via binding to the gamma-subunit of the GABAA receptor [19]. It undergoes
hepatic metabolism via hydroxylation from CYP 3A4 and 3A5, which forms the active metabolite
1-hydroxymidazolam that is renally excreted [25]. As a cytochrome P450 substrate, levels of midazolam
are affected by AEDs and other medications that are inducers or inhibitors.
When using midazolam for RSE, a loading dose of 0.2 mg/kg at 2 mg/min is recommended,
with repeated boluses of 0.2–0.4 mg/kg [7] until seizures have stopped. A continuous infusion should
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be started at 0.05–0.2 mg/kg/h and titrated up to 2 mg/kg/h as required, although rates as high as
2.9 mg/kg/h have been described [26]. Fernandez et al. compared high- and low-dose midazolam
treatment protocols (if needed, as high as 2.9 mg/kg/h and 0.4 mg/kg/h, respectively) and found that
the group treated under the high dose protocol had fewer withdrawal seizures after weaning off the
midazolam infusion and had a significantly lower discharge mortality with no difference in hospital
complications (aside from a higher incidence of hypotension, which did not affect outcome). However,
though the study showed that these higher doses were probably safe, the median maximum doses in
the high- and low-dose groups were 0.4 mg/kg/h and 0.2 mg/kg/h, respectively, with only half of the
patients in the high-dose protocol group receiving doses higher than 0.2 mg/kg/h; meanwhile patients
in the high-dose protocol also received treatment earlier, suggesting that an overall more aggressive
approach to treatment may be more effective. Unfortunately, there have been no prospective trials
comparing midazolam infusions to other cIV anesthetics for the treatment of RSE.
4. Propofol
For many, propofol is a practical alternative to midazolam as the third-line agent anesthetic of
choice for RSE, chiefly because of its ultra-fast onset and rapid clearance even, in many cases, after
extended infusion. Its half-life after a high-dose prolonged infusion is about 10 min for the first phase,
although subsequent phases may take hours to days [27]. This property is due to the drug’s high lipid
solubility, allowing it to cross the blood-brain barrier and redistribute to peripheral tissues rapidly,
where it also tends to accumulate after prolonged infusions [28,29]. Its most frequent side effects
are hypotension, which often requires the use of vasopressors for the higher doses that are utilized
in RSE, and respiratory depression, though it may also cause bradycardia. Hypertriglyceridemia is
also common given its formulation as a lipid emulsion, and significantly elevated serum triglycerides
(i.e., exceeding 400 mg/dL) should prompt consideration about alternative therapy. More seriously,
propofol carries with it the major caveat of an uncommon but life-threatening adverse effect known
as propofol-related infusion syndrome (PRIS), which was initially described in children, but has also
been associated with prolonged infusions as in those used for RSE [30]. This is manifested as severe
metabolic acidosis, rhabdomyolysis, renal failure, and circulatory collapse, and has been attributed
to mitochondrial dysfunction that leads to a mismatch between energy supply and demand [31].
Prolonged use of propofol should, therefore, prompt routine monitoring of lactate, creatine kinase,
triglycerides, and potassium. Due to the risk of PRIS and reported case reports of fatal events, propofol
is not routinely recommended in pediatric patients and is contraindicated for use in young children [7].
Despite this risk, multiple case series [16,28,31,32] and a meta-analysis [9] appear to show that
its complication rate and efficacy is comparable to other cIV anesthetics used for RSE. (Interestingly,
there have also been some case reports about seizure-like phenomena occurring during propofol use,
primarily in the anesthesia literature and especially during induction and emergence, however this
appears to be a rare occurrence [33]). Again, prospective data is limited, aside from a small prospective
trial comparing propofol with pentobarbital that was only able to enroll 24 patients [8].
Propofol’s mechanism of action involves modulating GABAA receptors; in addition, however,
it also acts on sodium and calcium channels, and likely also has an antagonistic effect on NMDA
receptors [26,34]. Its metabolism is primarily through hepatic glucuronidation with subsequent
renal excretion, though a significant portion is also metabolized by cytochrome P450 isozymes.
However the redistribution of propofol from blood into tissues is much more rapid than from
peripheral compartments back into the blood, so clearance is also highly dependent on the total
volume of distribution.
Propofol for RSE is typically given as a loading dose of 1–2 mg/kg followed by a continuous
infusion, which can range from a starting rate of 20 mcg/kg/min up to as high as 200 mcg/kg/min
(though infusions higher than 80 mcg/kg/min should be used cautiously due to the risk of PRIS) [7].
Propofol is formulated as a lipid emulsion and has a caloric value of 1.1 kcal/mL which should be
accounted for when calculating nutritional requirements.
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5. Barbiturates: Pentobarbital and Thiopental
Until the advent of propofol and midazolam infusions, barbiturates were the agents of choice for
treating RSE. Traditionally, pentobarbital has been the barbiturate used in the U.S., while thiopental is
more commonly used in Europe. In current practice, though, barbiturates are typically reserved
for the management of RSE that fails to respond to midazolam and/or propofol, also known
as super-refractory SE (SRSE). Though the class of medications has a long history of successful
use [4,9,35–42], a host of major side effects limit its appeal given the other available options. These
side effects include severe hypotension (often necessitating the use of vasopressors) and overall
cardiovascular depression, respiratory depression, paralytic ileus, lowering of core body temperature,
immune suppression, and a potential risk for pancreatic and hepatic dysfunction. The IV formulation
of pentobarbital (but not thiopental) also contains propylene glycol, leading to a risk of propylene
glycol toxicity with prolonged infusions.
In their favor, however, are several studies that suggest a possible benefit over other cIV-AEDs.
A meta-analysis of 28 studies comparing midazolam, propofol, and pentobarbital infusions for RSE
suggested that treatment with pentobarbital was associated with a significantly lower frequency of
short-term treatment failure, breakthrough seizures, and changes to a different continuous infusion [9].
In a more recent single-center retrospective study, episodes of RSE in which barbiturates were used
were associated with EEG burst suppression or complete suppression significantly more frequently
than episodes in which they were not given. However they were also associated with significantly
longer hospital stays for surviving patients, while mortality and likelihood of returning to clinical
baseline at discharge did not differ significantly compared to propofol or midazolam [4]. Another
recent single-center retrospective study confirmed these findings, and also found that weaning from
pentobarbital appeared to be more successful (with lower incidence of withdrawal seizures) when
phenobarbital was added before weaning [42]. Finally, a previously-mentioned, small randomized trial
comparing pentobarbital with propofol showed comparable mortality and return to clinical baseline
between the two, along with similar rates of infection and hypotension, though pentobarbital was
associated with a significantly longer duration of mechanical ventilation [8].
Both pentobarbital and thiopental exert their effects via binding to the GABA receptor and
prolonging the duration of opening of the associated chloride channel (as opposed to the increased
frequency of opening caused by benzodiazepines), enhancing its inhibitory effects [43]. Since both
barbiturates are highly lipophilic, they quickly distribute into the central nervous system, allowing
for a fast time to onset for pentobarbital (15–20 min), and an ultra-fast time to onset for thiopental
(30–60 s). However this may also result in deposition into peripheral tissues and saturation of metabolic
pathways even after relatively short infusions, leading to nonlinear metabolism and a long half-life
(ranging from 15 to 60 h for pentobarbital, and 11 to 36 h for thiopental) [44–47]. They both also
have a tendency toward autoinduction which typically takes days to occur, as well as numerous drug
interactions. Both pentobarbital and thiopental are hepatically metabolized; the main metabolite of
thiopental is pentobarbital. Both pentobarbital [48] and thiopental [49] are highly protein-bound in
plasma, ranging from 60% to 90%.
When used for RSE, pentobarbital is administered as a loading dose of 5–15 mg/kg, with an
additional 5–10 mg/kg as needed to obtain the desired effect (infused at a rate ď 50 mg/min); a
continuous infusion is started at a rate ranging from 0.5 to 5 mg/kg/h [7]. Thiopental is administered
as a loading dose of 2–7 mg/kg (infused at a rate ď 50 mg/min), with additional doses of 1–2 mg/kg
as needed, followed by a continuous infusion at a rate of 0.5–5 mg/kg/h. Therapeutic monitoring
of pentobarbital levels may be useful for patients where brain death is considered, but should not
be used to guide therapy for RSE. As mentioned in the retrospective study above, it may also be
preferable to start phenobarbital in anticipation of weaning pentobarbital, to potentially reduce the
risk of withdrawal seizures [42].
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6. Ketamine
Ketamine has emerged as a more recent addition to the arsenal of cIV-AED treatment for
RSE, primarily due to its alternative mechanism, though current evidence only supports its use
in conjunction with other anesthetics. As opposed to the agents mentioned above, all of which act
on the GABA receptor, ketamine is an antagonist on the N-methyl D-aspartate (NMDA) receptor,
thereby inhibiting glutamate activity. It has a very high lipid solubility leading to a fast onset and
extensive distribution, with an elimination half-life of around 2–3 h. Metabolism is primarily hepatic,
with oxidation via the cytochrome P450 system (especially CYP3A4) predominantly into the active
metabolite norketamine, which is then glucuronidated and excreted in urine and bile [50].
Its side effect profile is also generally favorable, as it is not associated with cardiac depression
and hypotension as with the other IV anesthetics, but instead induces a positive sympathetic response,
sometimes leading to drug-induced hypertension. Note, however, that in certain patients these cardiac
effects may be detrimental, especially in those with coronary disease or significant cardiomyopathy.
Prior studies had raised concern about the risk of increased intracranial pressure, but more recent
studies show no changes in intracranial pressure with the use of ketamine [51,52]. Though it has potent
anesthetic and analgesic properties, ketamine is not typically associated with respiratory depression,
although hypersalivation may become an issue. Meanwhile, patients who regain consciousness after
ketamine is stopped may experience psychiatric emergence phenomena, including agitation, confusion,
and psychosis.
Though experience with ketamine for RSE is more limited than with the other cIV-AEDs, a
number of case reports and case series detail its use [51,53–63]. Both a multi-center retrospective
study by Gaspard et al. [51] and a meta-analysis that included it, along with 22 other studies [63],
showed that ketamine appeared to contribute to seizure control in RSE for approximately 57% of
adult patients—however, outcomes and more detailed information for most of these patients in the
meta-analysis was not available. In the study by Gaspard et al., ketamine was thought to be likely
primarily responsible for seizure control in 32% of RSE episodes, while early response to ketamine
was also associated with a significantly improved mortality rate. Of note, because ketamine is often
started only after other anesthetic drugs have failed, there remains the possibility that its efficacy may
be higher if introduced earlier.
There has been significant variation in reported dosing, but median loading doses appear to be in
the range of 1–2 mg/kg, with a continuous infusion ranging anywhere from 1 to 10 mg/kg/h, based
on the cited reports. Importantly, in almost all cases, ketamine was initially added to at least one other
cIV-AED with subsequent weaning of other anesthetics; evidence is lacking as to its potential efficacy
as a stand-alone cIV-AED. In the meantime, expert opinion suggests that it be preferentially used in
conjunction with another anesthetic, preferably one with GABAergic action.
7. Controversies of Prolonged Anesthetic Use
Aside from the adverse effects listed above for individual anesthetic agents, prolonged anesthetic
use comes with its own set of possible repercussions, and these have become more widely recognized.
This has led to controversy about whether or not treatment of RSE with cIV anesthetic drugs may
actually worsen outcomes, as suggested by several recent observational studies.
Kowalski et al. [64] found that anesthetic use predicted poor outcome and death in SE, with
patients receiving these drugs having a three-fold relative risk of poor outcome compared to those
who did not (though no attempts were made in this study to adjust for possible confounders). A study
by Sutter et al. [65] showed that patients receiving anesthetics had four times more infections during
SE and a nearly three-fold relative risk for death, despite attempts being made to account for possible
confounders, such as SE duration and severity, other antiepileptic drugs used, and degree of overall
critical illness. Marchi et al. [66] echoed these findings in a larger study that was also adjusted for
possible confounders, with a subgroup analysis that also showed the association with poor outcome
was strongest in patients with more benign SE subtypes (i.e., absence, simple partial, or even complex
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partial SE). This may be deceiving, however, as such SE subtypes are rarely treated with cIV-AEDs by
experienced practitioners, and their inclusion may have been responsible for any significant findings
in the study.
Above all, perhaps the biggest criticism of these studies is that, even with attempts made to
account for confounding factors, there was likely some degree of inherent bias in prescribing anesthetic
agents to patients who were likely more ill, in ways that could not necessarily be captured by the
authors’ analyses. Though they do raise valid questions about the possible harms associated with
cIV-AEDs, caution should be used in interpreting these studies in such a way as to meaningfully
affect clinical practice, at least until high-quality prospective evidence becomes available. Meanwhile,
the general intensive care literature has raised awareness of another issue, suggesting that sedation,
in general, especially in higher doses, appears to be associated with higher incidences of cognitive
dysfunction, as described in a recent meta-analysis [67].
8. Conclusions
RSE carries with it a high morbidity and mortality regardless of treatment, though more aggressive
management aimed toward early seizure cessation may improve outcomes. Multiple anesthetics have
been shown to be effective in treating RSE, each with their own pros and cons but, unfortunately, there
is not yet strong evidence from prospective trials to guide specific management with regards to choice
of anesthetic and duration of treatment. Until such trials do exist, current clinical practice guidelines
allow for flexibility in choice of anesthetic, so that the decision can be tailored to each individual case.
Author Contributions: All authors contributed to drafting and revising the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
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